SIMCERE PHARMAC. GRP LTD (S2P) — Cash Flow Reinvestment Rate
SIMCERE PHARMAC. GRP LTD (S2P) has a Cash Flow Reinvestment Rate of 0.69x as of December 2025, reinvesting €1.39 Billion (capex €862.20 Million plus investments €-524.90 Million) from operating cash flow of €2.01 Billion. See SIMCERE PHARMAC. GRP LTD free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
SIMCERE PHARMAC. GRP LTD Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for SIMCERE PHARMAC. GRP LTD across 4 annual periods. For the full cash flow conversion analysis, see S2P operating cash flow.
Annual Cash Flow Reinvestment Rate for SIMCERE PHARMAC. GRP LTD (2022–2025)
Year-by-year capital reinvestment analysis for SIMCERE PHARMAC. GRP LTD. See S2P free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.69x | €1.39 Billion | €2.01 Billion | €862.20 Million | ▼ -24.3% |
| 2024 | 0.91x | €1.27 Billion | €1.39 Billion | €762.57 Million | ▼ -92.6% |
| 2023 | 12.32x | €1.86 Billion | €151.05 Million | €979.86 Million | ▲ +1340.9% |
| 2022 | 0.85x | €1.16 Billion | €1.35 Billion | €678.00 Million | — |